1o41 Citations

Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors.

Abstract

Results from a novel approach which uses protein crystallography for the screening of a low affinity inhibitor fragment library are analyzed by comparing the X-ray structures with bound fragments to the structures with the corresponding full length inhibitors. The screen for new phospho-tyrosine mimics binding to the SH2 domain of (pp60)src was initiated because of the limited cell penetration of phosphates. Fragments in our library typically had between 6 and 30 atoms and included compounds which had either millimolar activity in a Biacore assay or were suggested by the ab initio design program LUDI but had no measurable affinity. All identified fragments were located in the phospho-tyrosine pocket. The most promising fragments were successfully used to replace the phospho-tyrosine and resulted in novel nonpeptidic high affinity inhibitors. The significant diversity of successful fragments is reflected in the high flexibility of the phospho-tyrosine pocket. Comparison of the X-ray structures shows that the presence of the H-bond acceptors and not their relative position within the pharmacophore are essential for fragment binding and/or high affinity binding of full length inhibitors. The X-ray data show that the fragments are recognized by forming a complex H-bond network within the phospho-tyrosine pocket of SH2. No fragment structure was found in which this H-bond network was incomplete, and any uncompensated H-bond within the H-bond network leads to a significant decrease in the affinity of full length inhibitors. No correlation between affinity and fragment binding was found for these polar fragments and hence affinity-based screening would have overlooked some interesting starting points for inhibitor design. In contrast, we were unable to identify electron density for hydrophobic fragments, confirming that hydrophobic interactions are important for inhibitor affinity but of minor importance for ligand recognition. Our results suggest that a screening approach using protein crystallography is particularly useful to identify universal fragments for the conserved hydrophilic recognition sites found in target families such as SH2 domains, phosphatases, kinases, proteases, and esterases.

Articles - 1o41 mentioned but not cited (2)

  1. Research on the Mechanism of Kaempferol for Treating Senile Osteoporosis by Network Pharmacology and Molecular Docking. Tang F, Zhang P, Zhao W, Zhu G, Shen G, Chen H, Yu X, Zhang Z, Shang Q, Liang, Jiang X, Ren H. Evid Based Complement Alternat Med 2022 6741995 (2022)
  2. Leaf Extract of Perilla frutescens (L.) Britt Promotes Adipocyte Browning via the p38 MAPK Pathway and PI3K-AKT Pathway. Chen F, Wu S, Li D, Dong J, Huang X. Nutrients 15 1487 (2023)


Reviews citing this publication (9)

  1. A decade of fragment-based drug design: strategic advances and lessons learned. Hajduk PJ, Greer J. Nat Rev Drug Discov 6 211-219 (2007)
  2. Fragment-based lead discovery. Rees DC, Congreve M, Murray CW, Carr R. Nat Rev Drug Discov 3 660-672 (2004)
  3. A new strategy for improved secondary screening and lead optimization using high-resolution SPR characterization of compound-target interactions. Huber W. J Mol Recognit 18 273-281 (2005)
  4. Survey of the year 2003 commercial optical biosensor literature. Rich RL, Myszka DG. J Mol Recognit 18 1-39 (2005)
  5. Lessons from Hot Spot Analysis for Fragment-Based Drug Discovery. Hall DR, Kozakov D, Whitty A, Vajda S. Trends Pharmacol Sci 36 724-736 (2015)
  6. 4-Hydroxyphenylpyruvate dioxygenase inhibitors in combination with safeners: solutions for modern and sustainable agriculture. Ahrens H, Lange G, Müller T, Rosinger C, Willms L, van Almsick A. Angew Chem Int Ed Engl 52 9388-9398 (2013)
  7. Dehydroamino acids: chemical multi-tools for late-stage diversification. Bogart JW, Bowers AA. Org Biomol Chem 17 3653-3669 (2019)
  8. The discovery of novel protein kinase inhibitors by using fragment-based high-throughput x-ray crystallography. Gill A, Cleasby A, Jhoti H. Chembiochem 6 506-512 (2005)
  9. Three-Dimensional Interactions Analysis of the Anticancer Target c-Src Kinase with Its Inhibitors. Jha V, Macchia M, Tuccinardi T, Poli G. Cancers (Basel) 12 E2327 (2020)

Articles citing this publication (18)